Drug review: Carfilzomib
Carfilzomib is a second generation proteasome inhibitor approved for use in relapsed/ refractory multiple myeloma. The mechanism of action, usage, toxicity and key trials involving this agent are briefly reviewed here.
Guardat en:
| Autor principal: | |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2019-01-01
|
| Col·lecció: | Indian Journal of Medical and Paediatric Oncology |
| Matèries: | |
| Accés en línia: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=1;spage=130;epage=131;aulast=Ganesan |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|